Ras
Les protéines Ras sont de petites GTPases qui agissent comme des commutateurs moléculaires dans la voie de signalisation MAPK, contrôlant la croissance, la différenciation et la survie cellulaires. Ras activé initie une cascade de signalisation qui inclut Raf, MEK et ERK, conduisant à diverses réponses cellulaires. Les mutations des gènes Ras sont courantes dans les cancers, faisant de Ras un point focal important de la recherche sur le cancer. Chez CymitQuimica, nous offrons une gamme de modulateurs de Ras pour soutenir vos recherches en biologie du cancer, transduction de signaux et développement thérapeutique.
155 produits trouvés pour "Ras"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
RGT-018
CAS :<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Formule :C27H24F3N7O2Couleur et forme :SolidMasse moléculaire :535.52KRAS inhibitor-32
CAS :<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Formule :C29H35FN10OS2Couleur et forme :SolidMasse moléculaire :622.78BMS-214662
CAS :<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Formule :C25H23N5O2S2Degré de pureté :99.58% - 99.58%Couleur et forme :SolidMasse moléculaire :489.61pan-KRAS degrader 1
CAS :<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Formule :C22H26N8OSCouleur et forme :SolidMasse moléculaire :450.56KRAS inhibitor-37
CAS :<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Formule :C32H33ClFN7O3Couleur et forme :SolidMasse moléculaire :618.10KRas G12C inhibitor 2
CAS :<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Formule :C32H37N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :567.68Dorrigocin A
CAS :<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Formule :C27H41NO8Couleur et forme :SolidMasse moléculaire :507.616ZCL279
CAS :<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Formule :C24H18N2O7S2Couleur et forme :SolidMasse moléculaire :510.539KRAS inhibitor-31
CAS :<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Formule :C33H30F3N5O4Couleur et forme :SolidMasse moléculaire :617.62XMU-MP-9
CAS :<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Formule :C19H13ClFN3OSCouleur et forme :SolidMasse moléculaire :385.84AM-001
CAS :<p>AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.</p>Formule :C24H16FN3OS2Couleur et forme :SolidMasse moléculaire :445.53KRAS inhibitor-35
CAS :<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Formule :C38H32F4N6O3SCouleur et forme :SolidMasse moléculaire :728.76KRAS inhibitor-41
CAS :<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formule :C30H37FN10OSCouleur et forme :SolidMasse moléculaire :604.745Sosimerasib
CAS :<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Formule :C36H39ClFN7O4Couleur et forme :SolidMasse moléculaire :688.191KRAS G12D inhibitor 28
CAS :<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Formule :C35H32Cl2FN5OCouleur et forme :SolidMasse moléculaire :628.57
